Emerging studies are generating significant interest surrounding Novo Nordisk's new drug , a novel dual agonist targeting GLP-1 and amylin . Unlike existing obesity solutions, this treatment seems to offer more decreases in weight and boost metabolic outcomes in preliminary results. Although further investigation is needed to completely understand